1. Fifty years of the mitochondrial pyruvate carrier: New insights into its structure, function, and inhibition.
- Author
-
Tavoulari S, Sichrovsky M, and Kunji ERS
- Subjects
- Male, Humans, Mitochondria metabolism, Mitochondrial Membranes metabolism, Mitochondrial Proteins metabolism, Pyruvic Acid metabolism, Monocarboxylic Acid Transporters metabolism, Mitochondrial Membrane Transport Proteins chemistry, Mitochondrial Membrane Transport Proteins metabolism
- Abstract
The mitochondrial pyruvate carrier (MPC) resides in the mitochondrial inner membrane, where it links cytosolic and mitochondrial metabolism by transporting pyruvate produced in glycolysis into the mitochondrial matrix. Due to its central metabolic role, it has been proposed as a potential drug target for diabetes, non-alcoholic fatty liver disease, neurodegeneration, and cancers relying on mitochondrial metabolism. Little is known about the structure and mechanism of MPC, as the proteins involved were only identified a decade ago and technical difficulties concerning their purification and stability have hindered progress in functional and structural analyses. The functional unit of MPC is a hetero-dimer comprising two small homologous membrane proteins, MPC1/MPC2 in humans, with the alternative complex MPC1L/MPC2 forming in the testis, but MPC proteins are found throughout the tree of life. The predicted topology of each protomer consists of an amphipathic helix followed by three transmembrane helices. An increasing number of inhibitors are being identified, expanding MPC pharmacology and providing insights into the inhibitory mechanism. Here, we provide critical insights on the composition, structure, and function of the complex and we summarize the different classes of small molecule inhibitors and their potential in therapeutics., (© 2023 The Authors. Acta Physiologica published by John Wiley & Sons Ltd on behalf of Scandinavian Physiological Society.)
- Published
- 2023
- Full Text
- View/download PDF